“Treatment of Small Vessel Disease With the Paclitaxel Drug-Eluting Balloon” Is the Target Lesion the Culprit One?

2015 ◽  
Vol 28 (6) ◽  
pp. 614-614
Author(s):  
Ciprian Blendea ◽  
Imre Benedek ◽  
Monica Chiţu
Keyword(s):  
Small Vessel Disease ◽  
Target Lesion ◽  
Small Vessel ◽  
Vessel Disease ◽  
Drug Eluting ◽  
Drug Eluting Balloon

scholarly journals Treatment of Small Vessel Disease With the Paclitaxel Drug-Eluting Balloon: 6-Month Angiographic and 1-Year Clinical Outcomes of the Spanish Multicenter Registry

2015 ◽  
Vol 28 (5) ◽  
pp. 430-438 ◽  
Author(s):  
Beatriz Vaquerizo ◽  
Faustino Miranda-Guardiola ◽  
Eduardo Fernández ◽  
José Ramón Rumoroso ◽  
Josep Antoni Gómez-Hospital ◽  
...  
Keyword(s):  
Clinical Outcomes ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Vessel Disease ◽  
Drug Eluting ◽  
Drug Eluting Balloon ◽  
Multicenter Registry

P2806A novel sirolimus drug eluting stent for Small-Vessel Disease: results from en-ABL e-registry

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
L Testa ◽  
S Dani ◽  
D Desai ◽  
R Pandya ◽  
P Parekh ◽  
...  
Keyword(s):  
Stent Thrombosis ◽  
Small Vessel Disease ◽  
Large Vessel ◽  
Small Vessel ◽  
Drug Eluting Stent ◽  
Vessel Disease ◽  
Significant Difference ◽  
Myocardial Infraction ◽  
Drug Eluting

Abstract Objective The aim of the study was to assess the clinical outcome of Abluminus DES in patients with small vessels. Background Percutaneous coronary intervention (PCI) of small coronary vessel (≤2.75 mm) associated with more chances of restenosis and repeat revascularization even when drug eluting stent employed. Methods A total of 2,500 patients enrolled in en-ABL e-registry which is a prospective, multicentre observational post market registry. Out of 2,500 patients, 1,253 patients had small vessel (SV, ≤2.75 mm) while 1,247 had large vessel (LV, >3mm) disease. The primary endpoint was major adverse cardiac events (MACE) which is composite of cardiac death, target vessel myocardial infraction (TV-MI) and target lesion/vessel revascularization (TLR) at 1 year follow up. The secondary endpoint were stent thrombosis and MACE up to 2 years. Results Baseline characteristics were well matched in both groups. In the SV group had higher prevalence of diabetes as compared to large vessel 43.0% vs 25.7%. Total 1,400 lesions treated with 1,612 Abluminus DES and 1,569 lesions treated with 1,675 Abluminus DES in SV and LV groups respectively. The mean diameter of stent was 2.61±0.23 and 3.3±0.3 mm in SV and LV groups respectively. There was a significant difference in MACE in treatment groups (3.7% vs. 1.4%, p=0.004 respectively) at 1 year. No significant differences were observed between SV and LV groups in terms of death/myocardial infarction or stent thrombosis. There were increment of only one TLR and no stent thrombosis reported at 2-year follow-up. Conclusion This result suggests the efficacy and safety of novel Abluminus DES in small vessel disease.

scholarly journals 012 Five-year clinical outcome in elderly population with small vessel disease treated with drug-eluting versus bare-metal stenting

2012 ◽  
Vol 4 (1) ◽  
pp. 4
Author(s):  
Etienne Puymirat ◽  
Fabio Mangiacapra ◽  
Aaron Peace ◽  
Yiannis Ntarladimas ◽  
Micaela Conte ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Elderly Population ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Bare Metal ◽  
Vessel Disease ◽  
Drug Eluting

AS-209 Newer Generations versus First Generation Drug-Eluting Stents in Small Vessel Disease

2012 ◽  
Vol 109 (7) ◽  
pp. S105
Author(s):  
Seung-Woon Rha ◽  
Amro Elnagar ◽  
Se Yeon Choi ◽  
Byoung Geol Choi ◽  
Sung Il Im ◽  
...  
Keyword(s):  
First Generation ◽  
Small Vessel Disease ◽  
Small Vessel ◽  
Drug Eluting Stents ◽  
Vessel Disease ◽  
Drug Eluting
Sign in / Sign up

Export Citation Format

Share Document